CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 22,014 enrolled
Drug / intervention
Study Drugdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01270711
NCT01270711N/ACompleted
CompareCT.gov

Study on Utilization Of Cabergoline For Compliance With Risk Minimization Activities (SUCRE)

Pfizer·observational·Posted Jan 5, 2011·Updated May 2, 2014

In Brief

An observational study evaluating Study Drug for Parkinson's Disease and Hyperprolactinemia. Completed, enrolled 22,014 participants.

Detailed Summary

The overall goal of this study will be to assess and monitor the adherence to and effectiveness of the new prescribing guidelines for cabergoline. Specific objectives will be to assess: 1. The indication for use of cabergoline (Parkinson, hyperprolactinemia, other) 2. Prior treatment strategies in patients who start cabergoline treatment for Parkinson's Disease 3. The percentage of cabergoline users who are prescribed doses above 3 mg per day 4. Whether cabergoline users are monitored by echocardiography prior and during treatment. 5. The incidence and prevalence of valvular fibrosis

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson's Disease, Hyperprolactinemia
Countries--
Collaborators--

Timeline

N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJan 5, 2011
Enrollment StartNov 1, 2010
Primary CompletionFeb 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 15.5 years ago

Interventions

Study Drugdrug

non interventional study - usage as per usual care